Home > Search Clinical Trials > Other

IRB No. 16-055-2 (Dr. David Steffens, PI): Department of Psychiatry: Adult Repository

The purpose of the repository is to prospectively collect biological samples along with clinical data to facilitate future research studies and pilot analysis related to medical and behavioral health research.

IRB No. 22-255-2 (Dr. Zhichao Fan, PI): Mechanisms and Roles of Integrin Activation of Cystic Fibrosis Leukocytes

The immune system is the body';s defense against infectious organisms and other invaders. Integrins are key mediators in immunity for the recruitment of white cells which play critical roles in inflammatory diseases. Insights about Integrin function hold out the prospect of improved disease prevention and drug discovery. Integrin molecules stick to body surfaces or cells. They are vital to the successful functioning of the inflammatory response at the source of an insult. In response to inflammation or infection, white cells stick to nearby blood vessels and then crawl along the surface until they can squeeze out of the blood vessel into tissues where they must act. Studying and super imaging these mechanisms and the roles of integrin during this activation will bring new insights about leukocyte recruitment and leukocyte immune functions as well as invite discovery of novel treatments for infectious and inflammatory diseases. This project is investigating how integrins may also affect blood vessels as commonly seen in human heart disease.

IRB No. 23-134-2 (Dr. Julie Robison, PI): UConn Pepper Center (OAIC) Recruitment Volunteer Registry

Objective/Goals: The Research Volunteer Registry (RVR) is a mailing list that is used to invite and share opportunities to participate in future research studies and to community educational events the UConn Pepper Center will host.

IRB No. 24-023J-2 (Dr. Paul Robson, PI): An open resource of human induced pluripotent stem cells lines from diverse population groups

Specific Aims 1. Establish well characterized male and female human induced pluripotent stem cell lines (iPSCs) lines from genetically diverse healthy individuals. 2. Establish clonal sublines from a subset of karyotypically normal iPSC lines and assess their capacity for differentiation and suitability for genome editing. 3. Expand and archive a selected subset of normal, pluripotent iPSC clonal sublines and perform whole genome sequencing (WGS). 4. Release selected iPSC sublines and their genome sequences for distribution to the research community on a cost-recovery basis. Design and Outcomes Participants will provide blood samples (10-15ml) at a single visit for development of iPSC lines with consent for future research use and distribution of iPSC lines to the research community and sharing of genomic data in publicly accessible databases. Sample Size, Population, Interventions and Duration: Up to 103 self-reported healthy adult participants (both male and female) will be enrolled in the study for a single visit lasting 30 minutes. While somewhat restricted based on enrollment we will aim to recruit individuals with the following self-reported ancestry: African/African American (n=30), Latin American/Hispanic (n=20), East/Southeast Asian (n=8), South Asian (n=14), European/White (n=8), Middle Eastern (n=10), and Other (n=13) populations.

IRB No. 24-110-2 (Dr. Francesco Celi, PI): Exploring Treatment Experiences in Hypothyroidism Secondary to Surgery and Autoimmune Conditions

Our project seeks to understand if our current mainstay treatment for hypothyroidism (levothyroxine) is effective in treating the symptoms our patients are telling us. There have been several publications in the literature to suggest that a significant proportion of patients continue experiencing hypothyroid symptoms despite attaining normal lab values. In this study, we will utilize focus groups to discuss patient's experiences with hypothyroidism and improvements or no improvements with treatment, as well as any burdens of treatment. We will also use a validated, thyroid-specific quality of life instrument ThyPro questionnaire.

IRB No. 24-186-1 (Dr. Francesco Celi, PI): Novel approaches to the treatment of hypothyroidism

Hypothyroidism is a common disease affecting up to 10% of the adult population, disproportionally more frequent in females. This condition is associated with dyslipidemia and increased cardiovascular risk1-4, which is not completely reversed following therapy. Despite its prevalence, there is a surprising lack of evidence-based information on the optimal treatment of hypothyroidism, likely because thyroid hormone replacement treatments have been in place well before the establishment of the current regulatory framework. This is a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study in which 90 patients with hypothyroidism (30 each group) will be randomized to six months of treatment with LT4/placebo, LT4/LT3 with LT3 administered once daily, or LT4/LT3 with LT3 administered twice daily. This study will identify information on feasibility, dosing, treatment scheme, and effect size of end-organ outcomes. If successful, this will inform future clinical trials that will provide evidence supporting or negating the use of LT4/LT3 combination therapy to treat hypothyroidism.